Sequence Bio is a Newfoundland and Labrador biotechnology company headquartered in St. John’s. On Canada’s east coast, we’re a committed team of local and global experts leveraging our province’s founder effect to find the true signals of disease to power life-changing medicines.
By combining founder population multi-omics, real-world patient data, and well-characterized phenotypes, we are taking a systems biology approach to discover better drug targets, faster.
Sequence Bio is leading the NL Genome Project
The NL Genome Project is a large-scale genomics research study that is researching the DNA (through a simple saliva sample) and medical information of 10,000 volunteers in Newfoundland and Labrador in this pilot phase.
The NL Genome Project is currently enrolling eligible patients of participating doctors throughout the province. Learn all about this research at the NL Genome Project website!
NL Genome Project WebsiteOur Commitment
Sequence Bio is committed to benefiting the lives of individuals, families, and communities in Newfoundland and Labrador for generations to come. We’ll share any discoveries from the NL Genome Project with researchers, policy makers, and doctors across the province, and return genetic findings to participants.
